TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8776965

Group type: EXPERIMENTAL
Intervention: Laparoscopic adrenalectomy for Cushing's syndrome
Number of subjects: 6

Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy for other adrenal tumors
Number of subjects: 6

Group type: COMPARATOR
Intervention: Open adrenalectomy for Cushing's syndrome
Number of subjects: 6
Study: 1281362

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH; Sandoparin) administered once daily subcutaneously at a fixed dosage
Number of subjects: 216

Group type: COMPARATOR
Intervention: Dextran 70 administered intravenously
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Dextran 70
Number of subjects: 216
Study: 3974451

Group type: EXPERIMENTAL
Intervention: Exercise training and constant weight
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inactive and weight loss
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercise training and weight loss
Number of subjects: 21

Group type: COMPARATOR
Intervention: Inactive and constant weight (control)
Number of subjects: 21
Study: 31533277

Group type: EXPERIMENTAL
Intervention: 15 µg dose of VLP vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 45 µg dose of VLP vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30397707

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 66

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 66
Study: 26164350

Group type: EXPERIMENTAL
Intervention: Yoga intervention (2 sessions per week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 40
Study: 25580784

Group type: EXPERIMENTAL
Intervention: NAVS naphthalan for OLP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAVS naphthalan for RAS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Topical betamethasone for RAS (Control)
Number of subjects: 18
Study: 22226929

Group type: EXPERIMENTAL
Intervention: firategrast 900 mg or 1200 mg
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: firategrast 600 mg
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: firategrast 150 mg
Number of subjects: 343

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 343
Study: 20359274

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paraffin pellets
Number of subjects: 90
Study: 17998087

Group type: EXPERIMENTAL
Intervention: Questionnaire plus invitation letter
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (invitation letter only)
Number of subjects: 270
Study: 15889358

Group type: EXPERIMENTAL
Intervention: Amoxicillin (1000 mg 3 times per day) for patients with positive urinary antigen test results
Number of subjects: 219

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg 2 times per day) for patients with negative urinary antigen test results
Number of subjects: 219
Study: 12479768

Group type: EXPERIMENTAL
Intervention: Standardized HRQL assessments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30)
Number of subjects: 214
Study: 9793914

Group type: EXPERIMENTAL
Intervention: Immersion technique
Number of subjects: 288

Group type: COMPARATOR
Intervention: Contact technique
Number of subjects: 288
Study: 8592955

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic use
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Historical physical activity
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Quadriceps strength
Number of subjects: 523

Group type: COMPARATOR
Intervention: Current cigarette smoking
Number of subjects: 523

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 523

Group type: COMPARATOR
Intervention: Current leisure-time physical activity
Number of subjects: 523

Group type: COMPARATOR
Intervention: Dietary calcium intake
Number of subjects: 523

Group type: COMPARATOR
Intervention: Vitamin D use
Number of subjects: 523

Group type: COMPARATOR
Intervention: Caffeine intake
Number of subjects: 523
Study: 2696507

Group type: EXPERIMENTAL
Intervention: IV labetalol, 0.25 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IV labetalol, 0.75 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 24
Study: 18493

Group type: EXPERIMENTAL
Intervention: 30 mg/day clobazam (HR 376)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 15 mg/day diazepam
Number of subjects: 34
Study: 31727662

Group type: EXPERIMENTAL
Intervention: Endobarrier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 0
Study: 28678392

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 26214167

Group type: EXPERIMENTAL
Intervention: Active movement coordination with a confederate in a 2-handed sawing task
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Interdependent self-construals (typical of Asian cultures)
Number of subjects: 2
Study: 23099653

Group type: EXPERIMENTAL
Intervention: Postradiation cisplatin and vincristine plus CCNU
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Postradiation cisplatin and vincristine plus cyclophosphamide
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Radiotherapy (2340 cGy craniospinal and 5580 cGy posterior fossa)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 379
Study: 21611972

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) intake (24%, n = 26)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal protein (NP) intake (18%, n = 21)
Number of subjects: 47
Study: 19387874

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention + Metformin (1500 g daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 25
Study: 16711496

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (0.5% ropivacaine, 20 mL, plus continuous infusion of 5 mL/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-dose sciatic nerve block (20 mL of 0.5% ropivacaine)
Number of subjects: 0
Study: 14709300

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% solution (Voltaren Ophthalmic)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Topical ketorolac tromethamine 0.5% solution (Acular)
Number of subjects: 34
Study: 10963923

Group type: EXPERIMENTAL
Intervention: Support from coworkers and supervisors
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Job efficacy
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Working in a methadone clinic
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Percentage of clients with HIV/AIDS
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 134
Study: 9036608

Group type: EXPERIMENTAL
Intervention: EHF therapy alone (group 1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: EHF therapy plus antibacterial drugs (group 2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 63
Study: 1480446

Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 64
Study: 3979723

Group type: COMPARATOR
Intervention: 10 g protein meal
Number of subjects: 35

Group type: COMPARATOR
Intervention: 20 g protein meal
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gastric pH maintained at 4.5
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gastric pH allowed to decrease
Number of subjects: 35
Study: 31102823

Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution (gentamicin 7 mg/ml + cefazolin 12 mg/ml + heparin 3500 IU/ml)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Lock solution with TauroLock-Hep500 (taurolidine citrate 4% + heparin 500 IU/ml)
Number of subjects: 127
Study: 29534661

Group type: EXPERIMENTAL
Intervention: Bortezomib (1 cycle at 1.3 mg/m2), methylprednisolone (500 mg/kg), 7 sessions of plasmapheresis, antithymocyte globulin (3-5 mg/kg/day for 10 days), rituximab (2 doses at 375 mg/m2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment
Number of subjects: 10
Study: 27187725

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention via conference call (CBC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention via conference call (BAC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group receiving usual care (CG)
Number of subjects: 61
Study: 26814104

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 µg·kg(‐1)·h(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 µg·kg(‐1)·h(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg·kg(‐1)·h(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 µg·kg(‐1)·min(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6-1.0 µg·kg(‐1)·h(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4-0.8 µg·kg(‐1)·h(‐1)
Number of subjects: 120
Study: 22830927

Group type: EXPERIMENTAL
Intervention: Education and Papilla Gown
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Gown only
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control
Number of subjects: 145
Study: 21680720

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells administered intradermally (10 million cells, once every 2 weeks for 4 administrations)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Engineered dendritic cells
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study: 18945593

Group type: EXPERIMENTAL
Intervention: Recovery (no psychotic or negative symptoms, living independently, GAF (f)>59, working or studying)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Institutionalization (either at hospital or supported housing)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Predictors of continuous illness course
Number of subjects: 265
Study: 16536764

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1522
Study: 12669389

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment methods from randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine
Number of subjects: 0
Study: 11595472

Group type: EXPERIMENTAL
Intervention: OCT (20 mg omeprazole + 2 x 250 mg clarithromycin + 2 x 500 mg tinidazole for 7 days)
Number of subjects: 320

Group type: COMPARATOR
Intervention: OAM (20 mg omeprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg metronidazole for 7 days)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: PAC (40 mg pantoprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg clarithromycin for 7 days)
Number of subjects: 320

Group type: COMPARATOR
Intervention: RBC-C (2 x 400 mg ranitidin bismuth citrate + 2 x 500 mg clarithromycin for 14 days)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: LCM (2 x 30 mg lansoprazole + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Number of subjects: 320

Group type: COMPARATOR
Intervention: RBC-CM (2 x 400 mg ranitidin bismuth citrate + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Number of subjects: 320
Study: 9402342

Group type: EXPERIMENTAL
Intervention: Combination therapy with three drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antibodies to VacA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antibodies to CagA
Number of subjects: 21
Study: 8428859

Group type: EXPERIMENTAL
Intervention: Closed-port intermittent nebulization (CN)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Open continuous nebulization (ON)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral route (OR)
Number of subjects: 21
Study: 3313099

Group type: EXPERIMENTAL
Intervention: L-baclofen
Number of subjects: 15

Group type: COMPARATOR
Intervention: racemic baclofen
Number of subjects: 15
Study: 29707864

Group type: EXPERIMENTAL
Intervention: 3D-MOT training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual strategy/math-based game (2048)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 27006332

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160mg) once daily
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study: 24941010

Group type: EXPERIMENTAL
Intervention: Combined administration of insulin and glucose, titrated to preserve normoglycemia (3.5‐6.1 mmol L(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard metabolic care (blood glucose 3.5‐10 mmol L(‐1))
Number of subjects: 26
Study: 23225820

Group type: EXPERIMENTAL
Intervention: Negative pressure drainage group (n=32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Natural drainage group (n=30)
Number of subjects: 62
Study: 21575130

Group type: EXPERIMENTAL
Intervention: N7-GP (dose of 12.5-100 μg kg(‐1))
Number of subjects: 40
Study: 18313674

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation for 3 months
Number of subjects: 70
Study: 16504397

Group type: EXPERIMENTAL
Intervention: Oral cortisol (30 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Relaxed test situation
Number of subjects: 31
Study: 12946546

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2.0% ophthalmic solution
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall eyedrop preference
Number of subjects: 59
Study: 10983647

Group type: EXPERIMENTAL
Intervention: d4T + ddI + IDV
Number of subjects: 205

Group type: COMPARATOR
Intervention: ZDV + 3TC + IDV
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 205

Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 205
Study: 9108190

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 14
Study: 8403154

Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine 100 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 48
Study: 3437302

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2 mg per night)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29206813

Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg, t.i.d)
Number of subjects: 20
Study: 27881136

Group type: EXPERIMENTAL
Intervention: CHWs trained to use rapid diagnostic tests (RDTs) for malaria diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHWs using presumptive diagnosis based on clinical signs and symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHWs prescribed artemisinin-based combination therapy (ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-referral treatment with rectal artesunate
Number of subjects: 0
Study: 25011077

Group type: EXPERIMENTAL
Intervention: Principal Component Analysis (PCA) applied to 19 inflammatory biomarkers
Number of subjects: 0
Study: 22782366

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heavyweight mesh (HW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 15950945

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LA) supplementation
Number of subjects: 0
Study: 12032519

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Other tocolytic
Number of subjects: 144

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Maternal serum ionized magnesium levels
Number of subjects: 144
Study: 9659136

Group type: EXPERIMENTAL
Intervention: Osteoscan peripheral dual energy X‐ray absorptiometer (pDXA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Single photon absorptiometer (SPA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Lunar dual energy X-ray absorptiometer (DXA)
Number of subjects: 57
Study: 7893296

Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Meperidine (75 mg)/Promethazine (25 mg)
Number of subjects: 42
Study: 2694346

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 82
Study: 102008

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 70
Study: 30077530

Group type: EXPERIMENTAL
Intervention: Intensive PD treatment (IPT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard PD treatment (CPT)
Number of subjects: 51
Study: 27746332

Group type: COMPARATOR
Intervention: Cemented partial dentures (C-PD, n=35)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Screwed partial dentures (S-PD, n=35)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fixed-detachable hybrid prostheses (HP, n=37)
Number of subjects: 107
Study: 24148695

Group type: EXPERIMENTAL
Intervention: High-intensity Aerobic Exercise (AE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-intensity non-aerobic Balance/Flexibility (BF)
Number of subjects: 50
Study: 21153699

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 84
Study: 20564351

Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Virologic nonresponders (NR)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Breakthrough or relapse (BT/R)
Number of subjects: 180
Study: 18498915

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ combination therapy
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Valsartan monotherapy
Number of subjects: 1668
Study: 15948086

Group type: EXPERIMENTAL
Intervention: Scheduled telephone calls by specially trained nurses promoting self‐management and guideline‐based therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 12013192

Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol 1,200 I.U. daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: ascorbic acid 2 g daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ascorbic acid 2 g plus d-alpha-tocopherol 1,200 I.U. daily
Number of subjects: 45
Study: 10412820

Group type: EXPERIMENTAL
Intervention: Smoking mothers (1-50 cigarettes/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Smoking mothers (5-50 cigarettes/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Smoking mothers (10-50 cigarettes/day)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (nonsmoking parents)
Number of subjects: 206
Study: 7772663

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5‐0.8 Vol.% and 70% nitrous oxide in oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg followed by continuous infusion of 6 mg/kg/h, and alfentanil 15 micrograms/kg followed by continuous infusion of 15 micrograms/kg/h
Number of subjects: 40
Study: 2108643

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 units)
Number of subjects: 0
Study: 444406

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, vincristine, adriamycin and 5‐fluorouracil)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (oophorectomy, tamoxifen or androgens)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DNCB+ patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study: 31718737

Group type: EXPERIMENTAL
Intervention: Authentic Connections Virtual Groups (short-term intervention)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: In-person version of Authentic Connections program (previous randomized trial)
Number of subjects: 5
Study: 28052931

Group type: EXPERIMENTAL
Intervention: L.A.D.I.E.S. intervention
Number of subjects: 418

Group type: COMPARATOR
Intervention: Faith-based program
Number of subjects: 418

Group type: COMPARATOR
Intervention: Non-faith-based program
Number of subjects: 418

Group type: COMPARATOR
Intervention: Self-guided program
Number of subjects: 418
Study: 26001243

Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine (0.1 mmol/kg)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 189
Study: 22902324

Group type: EXPERIMENTAL
Intervention: Allyl isothiocyanate (AITC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AITC-rich vegetables (M/C)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 46
Study: 20875219

Group type: EXPERIMENTAL
Intervention: Quetiapine-XR ≥ 300 mg/d
Number of subjects: 2864

Group type: EXPERIMENTAL
Intervention: Quetiapine-XR (600 mg/d and 800 mg/d)
Number of subjects: 2864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2864
Study: 19675115

Group type: EXPERIMENTAL
Intervention: Digital video disk-based exercise programme (six exercise types, six levels of difficulty)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Digital video disk-based exercise programme
Number of subjects: 53
Study: 17166312

Group type: EXPERIMENTAL
Intervention: Early Training Group (ETG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late Training Group (LTG)
Number of subjects: 0
Study: 15891649

Group type: EXPERIMENTAL
Intervention: Continuous Interleaved Sampling (CIS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Simultaneous Analog Stimulation (SAS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CIS
Number of subjects: 25

Group type: COMPARATOR
Intervention: SAS
Number of subjects: 25